Neurent Medical

Neurent Medical operates in the ENT medical-device market with a focused approach to chronic rhinitis, particularly symptoms associated with posterior nasal nerves. Its NEUROMARK® System uses minimally invasive radiofrequency neuromodulation rather than relying exclusively on recurring pharmaceutical treatment or more invasive surgery. The product’s differentiators include impedance-controlled energy delivery, real-time apposition confirmation, flexible multi-leaflet placement, and a reusable graphical-interface RF console paired with a single-use hand-held device. FDA 510(k) clearance and the establishment of CPT® code 31242 provide regulatory and reimbursement infrastructure that can support physician adoption in the United States. Its differentiation is therefore best assessed through product design and market access signals rather than direct share comparisons. The €62.5 million Series C and subsequent €25 million debt facility indicate substantial investor support for commercialization, while the 2026 clinical-results announcement adds evidence relevant to adoption. The primary market risks are execution in ENT sales channels, physician training, reimbursement uptake, and competition from medication, surgery, and alternative device-based rhinitis treatments.

Neurent Medical’s trajectory shows a progression from early device development into regulated commercialization. The company was founded in 2014 and raised a $11 million Series A in 2018, followed by a €20.6 million Series B, approximately $25.0 million, announced on Jan 20, 2021. A venture round in 2024 and the launch of a next-generation NEUROMARK® System after FDA 510(k) clearance on Jun 11, 2025 marked a shift toward product refinement and market deployment. The 2025 opening of a new Oranmore manufacturing facility added internal production capacity and was linked to plans to create 125 jobs by 2028. Growth accelerated in 2026: the company closed a €62.5 million Series C on Feb 11, 2026, reported positive randomized controlled trial results on Feb 24, 2026, and obtained a €25 million growth debt facility on Sep 9, 2026. The financing sequence suggests that equity capital funded clinical, regulatory, and commercial expansion, while debt was added once the company had a cleared product and manufacturing infrastructure. The main inflection point is the move from clinical and regulatory milestones to repeatable commercial execution. Public employee data confirms a team size in the 51–100 range, but detailed hiring metrics and revenue data are unavailable.